An a-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes

Clinical and Experimental Medicine

Volumn 10, Issue 2, 2010, Pages 139-141

  Tsunosue, Miwako ^a   Mashiko, Naomi ^a   Ohta, Yhukou ^a   Matsuo, Yoshito ^a   Ueda, Kouichi ^a   Ninomiya, Masayuki ^a   Tanaka, Sho Ichi ^a   Hoshiko, Masaru ^a   Yoshiyama, Yasutsugu ^a   Takeuchi, Masayoshi ^b   Ueda, Shin Ichiro ^c   Yamagishi, S I ^c  

^a YY Research Group   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; GLYCERALDEHYDE; ALPHA GLUCOSIDASE; ENZYME INHIBITOR;

ADULT; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; FEMALE; GLYCATION; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; LETTER; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; AGED; BLOOD; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; SERUM;

ACARBOSE; AGED; ALPHA-GLUCOSIDASES; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; GLYCERALDEHYDE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; SERUM;

EID: 77954685327     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-009-0074-9     Document Type: Letter

References (9)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
2. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621
3. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 39: 1577-1583
4. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S (2009) Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab 10:159-163
5. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 6:351-358
6. Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-2299
7. Kitahara Y, Takeuchi M, Miura K, Mine T, Matsui T, Yamagishi S (2008) Glyceraldehyde-derived advanced glycation end products (AGEs). A novel biomarker of postprandial hyperglycaemia in diabetic rats. Clin Exp Med 8:175-177
8. Jinnouchi Y, Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, Imaizumi T (2006) Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 6:191-193
9. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S (2008) Agents that block advanced glycation end product (AGE)- RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 17:983-996